104 related articles for article (PubMed ID: 32633026)
21. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
22. Selective targeting p53
Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
[TBL] [Abstract][Full Text] [Related]
23. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
24. Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis.
Ho CK; Li G
Br J Dermatol; 2005 Nov; 153(5):900-10. PubMed ID: 16225598
[TBL] [Abstract][Full Text] [Related]
25. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
26. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.
Xu J; Timares L; Heilpern C; Weng Z; Li C; Xu H; Pressey JG; Elmets CA; Kopelovich L; Athar M
Cancer Res; 2010 Aug; 70(16):6566-76. PubMed ID: 20682800
[TBL] [Abstract][Full Text] [Related]
27. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
28. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma.
Wu WS; Heinrichs S; Xu D; Garrison SP; Zambetti GP; Adams JM; Look AT
Cell; 2005 Nov; 123(4):641-53. PubMed ID: 16286009
[TBL] [Abstract][Full Text] [Related]
29. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
30. Mdm2 increases cellular invasiveness by binding to and stabilizing the Slug mRNA.
Jung CH; Kim J; Park JK; Hwang SG; Moon SK; Kim WJ; Um HD
Cancer Lett; 2013 Jul; 335(2):270-7. PubMed ID: 23438693
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.
Zheng M; Yang J; Xu X; Sebolt JT; Wang S; Sun Y
Anticancer Res; 2010 Sep; 30(9):3321-31. PubMed ID: 20944104
[TBL] [Abstract][Full Text] [Related]
32. Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53.
Chen Y; Xin H; Peng H; Shi Q; Li M; Yu J; Tian Y; Han X; Chen X; Zheng Y; Li J; Yang Z; Yang L; Hu J; Huang X; Liu Z; Huang X; Zhou H; Cui X; Li F
Cancer Res; 2020 Jun; 80(11):2175-2189. PubMed ID: 32066565
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.
Nör F; Warner KA; Zhang Z; Acasigua GA; Pearson AT; Kerk SA; Helman JI; Sant'Ana Filho M; Wang S; Nör JE
Clin Cancer Res; 2017 Feb; 23(4):1036-1048. PubMed ID: 27550999
[No Abstract] [Full Text] [Related]
34. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.
Ning Y; Hui N; Qing B; Zhuo Y; Sun W; Du Y; Liu S; Liu K; Zhou J
Cell Death Dis; 2019 May; 10(6):414. PubMed ID: 31138778
[TBL] [Abstract][Full Text] [Related]
35. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
[TBL] [Abstract][Full Text] [Related]
36. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
[TBL] [Abstract][Full Text] [Related]
37. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
[TBL] [Abstract][Full Text] [Related]
38. Tumor-specific induction of apoptosis by a p53-reactivating compound.
Hedström E; Issaeva N; Enge M; Selivanova G
Exp Cell Res; 2009 Feb; 315(3):451-61. PubMed ID: 19071110
[TBL] [Abstract][Full Text] [Related]
39. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
40. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Ray RM; Bhattacharya S; Johnson LR
Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
